Loading...
NeoGenomics reported a 12% increase in consolidated revenue to $165 million and a significant rise in adjusted EBITDA to $11 million. The company has raised its full-year revenue and adjusted EBITDA guidance.
Consolidated revenue increased by 12% to $165 million.
Clinical Services revenue grew by 15% to $141 million.
Adjusted EBITDA saw a 630% increase, reaching $11 million.
Net loss decreased by 23% to $19 million.
The company revised its full-year 2024 guidance, raising revenue guidance to $655 to $667 million and adjusted EBITDA to $33 to $37 million.
Analyze how earnings announcements historically affect stock price performance